• Recent news

  • ArcticZymes launches its first Proteinase enzyme

    (Tromsø 20 June 2018) Biotec Pharmacon ASA’s (OSE:BIOTEC) subsidiary ArcticZymes adds the first Proteinase enzyme to its portfolio. ArcticZymes’ Proteinase is a novel heat-labile enzyme easily inactivated after use. Gentle inactivation of the enzyme enables broader compatibility in the development of kits and products serving the In Vitro Diagnostic (IVD) and molecular…

    Continue reading

Latest presentation

First quarter 2018 results

Loading video...

Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) reported sales of NOK 14.2 million (18.2) in the first quarter of 2018, and a negative EBITDA of NOK 5.9 million (-4.1). Woulgan® generated sales of NOK 0.5 million during the first quarter whereas ArcticZymes generated sales of NOK 6.3 milllion. During the first quarter, results…

View more